Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hospira, Inc.
News We’re Watching: Premom Data Privacy Settlement, Labcorp Owes $372m For Patent Violations, Elixir Stent Trial Success
This week, the DC Attorney General announced a settlement with ovulation-tracking app Premom; a novel scoliosis treatment won FDA approval; research showed Fractyl Health’s Rejuva delivery system can deliver gene therapy directly to the pancreas; and BearCare recalled a thermometer over burn risks.
SCARDA: Japan’s Big Hope To Change Its Vaccine R&D Ecosystem
Japan's SCARDA is building networks with academia and industry to support new vaccine development, while offering support through funding and knowledge. But is that enough to overcome the shortcomings highlighted by the pandemic?
USPTO Has Not Seen ‘Deluge’ Of Inconsistent Statements From Applicants
Agency did not intend to ‘strong-arm or threaten’ anyone in its duty to disclose notice, patent office legal advisors say. Applicants should assess whether information required by FDA on new method of manufacturing or different formulation impacts patentability.
Biogen And Millennium May Be Ensnared In Tentacles Of Genentech’s Expired Cabilly Patent
Genentech claims Biogen and Millennium owe royalties on sales of Tysabri and Entyvio that were stockpiled when the Cabilly patent expired. Hospira faced similar litigation over its erythropoietin biosimilar and had to pay Amgen $70m in damages.
- Other Names / Subsidiaries
- Javelin Pharmaceuticals, Inc.
- Mayne Pharma Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.